Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication

• by Xinjun He, Qi Zhou, Min Zhang, Dandan Wang, Xinchang Xu

• July 7, 2026

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

• by Kathryn Wighton

• July 7, 2026

• 6 min

Dynamic activation of lytic cell death-related programs identifies CD14 as a candidate hub gene associated with secondary injury after spinal cord injury

• by Shenglong Wang, Ruoxiang Mei, Wenting Xu, Xiaochen Su, Menghao Teng, Xiaoxiao Lou, Chen Zhang, Shenghua Guo, Yingang Zhang

• July 6, 2026

Quantitative multi-slice spiral CT perfusion parameters as predictors of collateral status and 90-day functional outcome in acute ischemic stroke

• by Dan Zhu, Xiaozhou Ma, Yingzhi Jiao, Shuai Liu, Jinzhu Yan, Lixin Zhang

• July 6, 2026